Literature DB >> 7598484

The transmissible spongiform encephalopathies.

L G Goldfarb1, P Brown.   

Abstract

The human transmissible spongiform encephalopathies (TSEs), or prion diseases, are a group of rapidly progressive disorders characterized by a spectrum of clinical abnormalities that include cognitive impairment, ataxia, myoclonus, and visual, pyramidal, and extrapyramidal signs. They share a spongiform (vacuolar) degeneration and variable amyloid plaque formation. Examples of TSEs are kuru, an infectious disease; Creutzfeldt-Jakob disease (CJD), which may take an infectious, genetic, or sporadic form; and Gerstmann-Sträussler-Scheinker disease (GSS) and fatal familial insomnia (FFI), rare familial disorders. With the exception of FFI, all of these disorders have been experimentally transmitted to nonhuman primates and laboratory rodents. The pathogenic PrP protein accumulating in the brain of TSE patients is a protease-resistant and insoluble product of a precursor protein molecule of unknown function that is encoded by the PRNP gene on chromosome 20. Different mutations in this gene are responsible for various phenotypes of TSE in its familial form, and a polymorphism at codon 129 controls susceptibility to the infectious and perhaps sporadic forms of disease. TSEs are transmissible amyloidoses in which the host-encoded protein has the propensity to acquire a beta-sheet conformation and produce amyloid; the accumulation of amyloid eventually destroys the neurons and induces the deadly disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7598484     DOI: 10.1146/annurev.med.46.1.57

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  9 in total

1.  Conformational transitions in model silk peptides.

Authors:  D Wilson; R Valluzzi; D Kaplan
Journal:  Biophys J       Date:  2000-05       Impact factor: 4.033

2.  Codon 219 polymorphism of PRNP in healthy Caucasians and Creutzfeldt-Jakob disease patients.

Authors:  R Petraroli; M Pocchiari
Journal:  Am J Hum Genet       Date:  1996-04       Impact factor: 11.025

Review 3.  Anti-amyloid drugs: potential in the treatment of diseases associated with aging.

Authors:  R Kisilevsky
Journal:  Drugs Aging       Date:  1996-02       Impact factor: 3.923

4.  Ancestral origins and worldwide distribution of the PRNP 200K mutation causing familial Creutzfeldt-Jakob disease.

Authors:  H S Lee; N Sambuughin; L Cervenakova; J Chapman; M Pocchiari; S Litvak; H Y Qi; H Budka; T del Ser; H Furukawa; P Brown; D C Gajdusek; J C Long; A D Korczyn; L G Goldfarb
Journal:  Am J Hum Genet       Date:  1999-04       Impact factor: 11.025

5.  Rapid, high-throughput detection of PrPSc by 96-well immunoassay.

Authors:  Michelle L Kramer; Jason C Bartz
Journal:  Prion       Date:  2009-01-13       Impact factor: 3.931

6.  Microglia from Creutzfeldt-Jakob disease-infected brains are infectious and show specific mRNA activation profiles.

Authors:  Christopher A Baker; Daniel Martin; Laura Manuelidis
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

7.  Detection of Prions in Brain Homogenates and CSF Samples Using a Second-Generation RT-QuIC Assay: A Useful Tool for Retrospective Analysis of Archived Samples.

Authors:  Tibor Moško; Soňa Galušková; Radoslav Matěj; Magdalena Brůžová; Karel Holada
Journal:  Pathogens       Date:  2021-06-13

Review 8.  Ensuring the biologic safety of plasma-derived therapeutic proteins: detection, inactivation, and removal of pathogens.

Authors:  Kang Cai; Todd M Gierman; JoAnn Hotta; Christopher J Stenland; Douglas C Lee; Dominique Y Pifat; Steve R Petteway
Journal:  BioDrugs       Date:  2005       Impact factor: 5.807

9.  Loss of anti-Bax function in Gerstmann-Sträussler-Scheinker syndrome-associated prion protein mutants.

Authors:  Julie Jodoin; Micheal Misiewicz; Priya Makhijani; Paresa N Giannopoulos; Jennifer Hammond; Cynthia G Goodyer; Andréa C LeBlanc
Journal:  PLoS One       Date:  2009-08-14       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.